Core Viewpoint - Zhejiang Haisen Pharmaceutical Co., Ltd. has approved the use of idle raised funds for cash management, allowing up to RMB 300 million to be invested in low-risk, high-liquidity financial products, ensuring that it does not affect the normal operation of fundraising projects [1][3]. Group 1: Cash Management Implementation - The company has opened dedicated settlement accounts for cash management of raised funds at various securities firms, ensuring compliance with regulations [2]. - The accounts will only be used for the settlement of idle raised funds and will not be used for other purposes [2]. Group 2: Risk Control Measures - The company will adhere to relevant laws and regulations, including the "Regulations on the Supervision of Raised Funds by Listed Companies," to manage cash effectively and disclose information timely [2]. - Measures will be taken to control investment risks, including reporting potential risks and returns to the board's audit committee [3]. Group 3: Impact on the Company - The cash management of idle raised funds will not change the purpose of the funds or harm the interests of the company and its shareholders, ensuring normal business operations [3]. - This strategy is expected to improve the efficiency of fund utilization and increase returns on cash assets for the company and its shareholders [3].
海森药业: 关于开立募集资金现金管理产品专用结算账户的公告